200 results about "Myocardial hypertrophy" patented technology

The invention provides a pyrazolopyrimidine compound shown as a structural formula (I), a pharmaceutical composition taking the pyrazolopyrimidine compound as an active component, a preparation method of the pyrazolopyrimidine compound and the pharmaceutical composition as well as an application of the pyrazolopyrimidine compound and the pharmaceutical composition in preparation of a TRPC6 (Transient Receptor Potential Channel 6) adjustor probe medicine and related medicines for preventing and treating glomerulopathy and myocardial hypertrophy. The pyrazolopyrimidine compound and derivatives provided by the invention can be used to prepare medical preparations in various forms which comprise oral liquids, injections, pulmonary inhalation preparations and transdermal preparations, specifically injections, oral liquids, troches, capsules, granules, aerosols, dry powder inhalation, patches and the like.

The invention provides the construction for a farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector, which comprises the following steps of: sieving the most effective target sequence of an FDS (farnesyl diphosphate synthase) gene RNAi (RNA interference) in a tool cell 293T cell, synthesizing the double-stranded DNA of the most effective target sequence, connecting to a pGCSIL-GFP vector and successfully constructing the recombinant vector through enzyme cutting, sequencing and identification. Researches indicate that the constructed RNA interference vector LV-sh-FDS can downwards modulate the expression of an FDS mRNA (Messenger RNA) level in a neonatal rat cardiac myocyte, simultaneously can downwards modulate the expression of myocardial hypertrophy markers such as cell areas and marker genes beta-MHC (Myosin Heavy Chain) and BNP (Brain Natriuretic Peptide), additionally can effectively inhabit the activity of RhoA while downwards modulating the FDS, can be applied in preparing medicaments for treating myocardial hypertrophy diseases and also can be applied in preparing medicaments for cholesterol metabolic control.

A cardiac electro-stimulatory device and method for operating same in which stimulation pulses are distributed among a plurality of electrodes fixed at different sites of the myocardium in order to reduce myocardial hypertrophy brought about by repeated pacing at a single site and/or increase myocardial contractility. In order to spatially and temporally distribute the stimulation, the pulses are delivered through a switchable pulse output configuration during a single cardiac cycle, with each configuration comprising one or more electrodes fixed to different sites in the myocardium.

The invention relates to medical examination and diagnosis methods and instruments, in particular to a multi-dimensional electrocardiosignal imaging system and method. The body surface electric potential mapping technology and the electrocardio vector technology are integrated, a new non-invasive platform is provided for recording the heart-across-myocardium electrical activity information, and in other words, a new non-invasive body surface heart-across-myocardium electrical activity information imaging method and technology which are formed by combining the vector center 0 point galvanic coupling and body surface electric potential mapping technology and are similar to satellite positioning are provided. The non-invasive electrocardio function imaging method and technology for detecting heart-across-myocardium electrocardio activity information with the dissection positioning as a basis are provided. According to the multi-dimensional electrocardiosignal imaging system and method, the arrhythmia reason can be determined, the cardiac muscle diseases such as myocardial hypertrophy, cardiomyopathy, myocardial infarction and myocarditis can be diagnosed, and a brand new diagnosis tool is provided for fast diagnosing the heat diseases in real time.

The invention belongs to the traditional Chinese pharmaceutics field, and relates to an application of traditional Chinese medicine radix scrophulariae to the preparation of a drug for preventing and curing cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure. The invention researches the effect of the cardiac hypertrophy and ventricle reconstruction model of a plurality of mice and rats on the traditional Chinese medicine radix scrophulariae. The experimental results show that the radix scrophulariae water or the alcohol abstracts has evident function for preventing the cardiac hypertrophy, the ventricular remodeling and the chronic heart failure caused by various reasons, the mechanism is obviously related with the excessive activation of the neuroendocrine system such as a suppressing renin-angiotensin-aldosterone system and is related with the functions of blood pressure reduction, heart beat slowing and hemodynamics improvement. The figwort can be used for preparing the drug for preventing the diseases of cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure and for reducing the possibility of the incidence rate of arrhythmia and the sudden death of patients with cardiac hypertrophy, hypertrophic cardiomyopathy and chronic heart failure.

The invention relates to a preparation method and an application of an effective part of dracocephalum heterophyllum benth. The method comprises the steps that an aboveground part of the dracocephalum heterophyllum benth is smashed, extracted by an organic solvent, namely alcohol, and subjected to macroporous resin separation and purification to form the effective part of the dracocephalum heterophyllum benth. A preliminary activity screening test proves that the effective part of the dracocephalum heterophyllum benth obtained by the method has functions of lowering renal hypertension and rat blood pressure, and enhancing diastole and systole, and can also effectively prevent and treat hypertension complications including myocardial hypertrophy, renal injuries and vascular endothelial injuries. The method is simple in technology, low in production cost, and easy to control, and does not require high temperature or high pressure equipment, and the quality of the effective component is stable.

The invention provides a construction method for a miRNA (micro Ribonucleic Acid) transgenic mice model. In the construction method, a transgenic mouse with overexpression miR-27b in a myocardial cell is established by using a transgenic technology; the systematic phenotyping on the transgenic mouse finds that the mouse possibly has myocardial hypertrophy and heart function damage; the basic pathological changes of the mouse are similar to those of human hearts, therefore, with the establishment of the transgenic mouse model, a favorable animal model for researching the heart disease nosogenesis and researching and developing new drugs is provided.

The invention discloses application of adenine nucleotide translocator 1 (ANT1), and relates to the field of the treatment of cardiovascular diseases. Through down-regulating the level of the sulfydryl nitrosylation modification of the ANT1 in a myocardial cell, the occurrence of myocardial hypertrophy is effectively inhibited. A method comprises the following steps of transfecting a myocardial cell by utilizing an adenovirus with the modification site mutation of cysteine, and regulating and controlling the expression of the sulfydryl nitrosylation modification of ANT1 protein in a cell, andalso comprises the following steps of specifically transfecting the heat tissue of a mouse by utilizing an adeno-associated virus with the modification site mutation of the cysteine, and regulating and controlling the expression of the sulfydryl nitrosylation modification of ANT1 protein in the heart tissue. Therefore, the sulfydryl nitrosylation modification of the ANT1 protein can be used as a new important target for clinically treating the myocardial hypertrophy, and has potential clinical application value in the prevention and treatment of the myocardial hypertrophy.

The invention discloses application of a polypeptide able to specifically bind TRB3 or polypeptide derivative or polypeptide chimeric peptide in preparation of drugs or vaccines for prevention and/or treatment of hypertensive myocardial hypertrophy. The polypeptide has an amino acid sequence shown as SEQ ID NO:1, the amino acid sequence of the polypeptide derivative is a SEQ ID NO:1 derived amino acid sequence that is obtained by subjecting the amino acid sequence shown as SEQ ID NO:1 to substitution, deletion or adding by one or several amino acid residues and has the same activity to an amino acid residue sequence of SEQ ID NO:1, and the polypeptide chimeric peptide is formed by connecting the polypeptide or polypeptide derivative with a cell-penetrating peptide. The invention also further discloses a nucleotide fragment encoding the polypeptide or polypeptide derivative, and application of pharmaceutical compositions containing the polypeptide or polypeptide derivative or polypeptide chimeric peptide and the nucleotide sequence thereof in preparation of drugs or vaccines for prevention and/or treatment of hypertensive myocardial hypertrophy.

The invention belongs to the technical field of medicines, and particularly relates to 5'-AACGTT-3'-containing oligonucleotides, a functional analogue of the oligonucleotides, and usage of the oligonucleotides or the functional analogue of the oligonucleotides for preventing and curing myocardial hypertrophy and chronic heart failure. The oligonucleotides and the usage realize the function of the 5'-AACGTT-3'-containing oligonucleotides by using myocardial cells and animal hypertrophy models acknowledged in the academia at home and abroad. The experimental result shows that the 5'-AACGTT-3'-containing oligonucleotides can obviously restrain the expression of a landmark protein ANF (atrial natriuretic factor) and a beta-MHC (major histocompatibility complex) gene of the myocardial hypertrophy, and can restrain the increase of a superficial area of the myocardial cell, and the restrain function of the oligonucleotides depends on the dosage of the oligonucleotides.. In the whole experiment, the 5'-AACGTT-3'-containing oligonucleotides can obviously restrain the myocardial hypertrophy and the increase of the heart-body ratio, and the happening of myocardial necrosis can be reduced. The experiment result disclosed by the invention prompts that the 5'-AACGTT-3'-containing oligonucleotides is the medicine for effectively curing the myocardial hypertrophy and the heart failure.

The invention relates to a method for preparing CNPase mutant zebra fish, and confirms that a mutant model can spontaneously generate bradycardia and even heart failure accompanied by severe heart failure. According to the invention, a CRISPR-Cas9 technology is combined with a microinjection technology, CNPase is specifically knocked out, a CNPase mutant F1 generation is prepared, and confirmation is performed through a Sange sequencing method; and through hybridizing and screening, a zebra fish homozygous mutant strain with heart specificity marked with green fluorescence is prepared, and it is confirmed that the CNPase homozygous mutant zebra fish can spontaneously generate cardiac hypertrophy and partially develop to heart failure through cardiology and kinetics indexes. The CNPase mutant zebra fish is prepared, an animal model is provided for researching functions of CNPase, and particularly great convenience is provided for researching related diseases of bradycardia accompanied by severe heart failure.

The invention discloses a pharmaceutical composition of targeting circRNA (circular Ribonucleic Acid). The pharmaceutical composition comprises MFACR-siRNA (small interfering Ribonucleic Acid) nucleotide, a pharmaceutically acceptable carrier or virus carrier and an auxiliary material; the carrier is one or more of chitosan, cholesterol, nanoparticles and liposome, preferably, the liposome; the auxiliary material is one or more of mannitol, a phosphate buffering solution and saline, preferably, the phosphate buffering solution; the content of the MFACR-siRNA is 0.8 to 1.5 micrograms; the mass ratio of the MFACR-siRNA to the liposome is 1 to 1.25; the mass ratio of the carrier to the auxiliary material is 1 to 200. The pharmaceutical composition is used for treating and preventing myocardial infarction, myocardial ischemial injury, myocardial hypertrophy and myocardial fibrosis, and is dosed in an oral administration or injection manner; the injection is intravenous injection, muscle injection, intracoronary injection or direct myocardial injection. Compared with the prior art, the selected raw materials are scientific and reasonable; a preparation process is simple and the drug action is obvious; the application range is wide, the utilization is safe and reliable and the application is environment-friendly.

The invention discloses function and application of a Caspase activation and recruitment domain 3 (Card3) gene in a coronary atherosclerotic heart disease. The Card3 gene knockout mice and heart specific Card3 transgenic mice are taken as objects, and a research is carried out on a myocardial infarction model caused by blocking mice heart ramus descendens anterior arteriae coronariae sinistrae. The result proves that compared with WT mice, the cardiac infarction proportion, and the degrees of myocardial hypertrophy and fibrosis of the Card3 gene knockout mice are obviously inhibited, and the cardiac function is obviously improved; the phenotype of the Card3 transgenic mice is contrary to that of the Card3 gene knockout mice. Consequently, the Card3 gene can promote and increase development and progression of the coronary atherosclerotic heart disease, the Card3 can be used as a drug target for screening the drugs for treating the coronary atherosclerotic heart disease, and the inhibitor of the Card3 can be applied to preparation of a drug for treating the coronary atherosclerotic heart disease.

The invention belongs to the technical field of biology, and particularly relates to an EZH2 variable splicing site and an application thereof. Specific siRNA is used for knocking down two subtypes ofEZH2-L and EZH2-S respectively, and myocardial hypertrophy and heart failure models are established at the cellular level and the animal level respectively. Results show that after the EZH2-L is knocked down, the expression level of a myocardial hypertrophy pathological gene is obviously reduced, the myocardial cell area is reduced, and the heart weight is reduced; and after the EZH2-S is knockeddown, the expression level of the myocardial hypertrophy pathological gene is remarkably increased, the myocardial cell area is increased, the heart weight is increased, and the situation prompts that the EZH2-L and the EZH2-S have the effects of promoting and inhibiting myocardial hypertrophy and heart failure respectively. In addition, after the EZH2-L is knocked down, tumor cell proliferationis inhibited, and knock-down of the EZH2-S has no influence on tumor cell proliferation. The invention provides a new target and a new strategy for research and development of medicines for treating EZH2 gene related diseases.

The invention provides application of 3-hydroxyphenylacetic acid (3-HPA) in preparation of a drug for improving ventricular pathological reconstruction and/heart failure after myocardial infarction, and belongs to the technical field of biomedicine. The 3-HPA can improve cardiac functions after myocardial infarction, reduce heart fibrosis after myocardial infarction and improve the size of cardiacmuscle cells after myocardial infarction. Mouse animal model experiments show that the 3-HPA can improve cardiac functions of mice after rejection of intestinal florae from myocardial infarction miceby antibiotic treatment, reduce heart fibrosis after rejection of intestinal florae from myocardial infarction mice by antibiotic treatment and inhibit myocardial hypertrophy after rejection of intestinal florae from myocardial infarction mice by antibiotic treatment.

The invention relates to application of a qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia to preparation of a medicament for improving myocardial fibrosis and myocardial hypertrophy. The qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia is refined from active ingredients in radix astragali, root of red-rooted salvia, pseudo-ginseng and dalbergia heartwood extracted by modern technology. The invention aims to provide application of qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia to preparation of the medicament for improving myocardial fibrosis and inhibiting further myocardial hypertrophy. According to the application in the invention, after generation of ventriculus sinister hypertrophy, the qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia can improve myocardial fibrosis, substantially inhibit increase of wall thickness cardiac index and body mass index in ventriculus sinister diastasis, increase ejection fraction and shortening fraction of the ventriculus sinister and reduce scope of myocardial fibrosis.

The invention discloses circRNA MNCR nucleotide, a circRNA MNCR nucleotide containing pharmaceutical composition and application thereof. The pharmaceutical composition comprises the circRNA MNCR nucleotide, auxiliary materials, a virus vector or an embedding carrier, wherein the embedding carrier is cholesterol, nanoparticles or liposome and is preferably liposome; the virus vector is one or more of an adenovirus vector, a lentiviral vector and a retroviral vector and is an adenovirus vector preferably; the auxiliary material is one or more of mannitol, phosphate buffer and normal saline and is phosphate buffer preferably; infection titer of the circRNA MNCR virus vector is 10<16>PFU, and a mass ratio of the circRNA MNCR nucleotide to the liposome is 1:1.25; a mass ratio of the virus vector or the embedding vector to the auxiliary material is 1:200. The circRNA MNCR nucleotide and the circRNA MNCR nucleotide containing pharmaceutical composition can be used for prevention and treatment of myocardial hypertrophy, myocardial fibrosis, coronary heart disease and heart failure and prevention of myocardial fibrosis and myocardial remodeling. A preparation process of the pharmaceutical composition is simple, and evident efficacy, convenience in use and environment friendliness in treatment are realized.

The invention relates to the application of CP-1 siRNA in treating AngII induced cardiac hypertrophy. Experimental study proves that the CP-1 siRNA can inhibit cardiac hypertrophy in mice induced by AngII, weakens the degree of ventricular dilatation and the thickness of a ventricular wall, inhibits the expression of marker protein ANF, beta-MHC of the cardiac hypertrophy, inhibits cardiac fibrosis, and is an effective novel cardiac hypertrophy treatment drug.

The invention belongs to novel application of plantamajoside in resistance of myocardial hypertrophy and particularly relates to application of plantamajoside in preparation of anti-myocardial hypertrophy drugs. An isoproterenol is adopted for inducing a myocardial hypertrophy model of a mouse and an H9c2 cardiomyocyte hypertrophy model, and meanwhile, intervention is carried out on plantamajosidedifferent in concentration; cardiac functions of the mouse are evaluated through ultrasound, the heart of the mouse and the left ventricular are weighed, and the myocardial hypertrophy degree of themouse is evaluated. The area of H9c2 cardiomyocytes is observed by means of fluorescence staining, and results show that plantamajoside has a protection effect on isoproterenol-induced myocardial hypertrophy of the mouse and an inhibitory effect on isoproterenol-induced H9c2 cardiomyocyte hypertrophy. Plantamajoside is expected to be developed for clinical use in the anti-myocardial hypertrophy drugs.

Myocardial hypertrophy is a pathological change of a plurality of kinds of angiocardiopathy. The main mode is the heart remodeling comprising cardiac muscle cell hypertrophy and change of the interstitial tissue component mainly. In the present invention, the nitrate medicine is used in treatment for myocardial hypertrophy caused by various reasons and excellent therapy effect is obtained. Currently the nitrate medicine is extensively applied in treatment for the coronary heart disease, the heart colicky pain and heart failure. Preload of the heart and myocardial consumption of oxygen are reduced by extension of the venous system. The drugs used in clinical field currently comprise Nitroglycerin, Amyl Nitrite, dicho nitric acid sorbite, sorbide dinitrate, 5-isosorbide dinitrate, Nitroglycerin, pentanitrol ters and itramine tosylate.

The invention relates to application of an oral hypoglycemic peptide. The application is used for preparing a medicine or a medicine composition for treating or preventing diabetes complicated with cardiovascular diseases. The oral hypoglycemic peptide is polypeptide OHP2. The polypeptide can effectively improve myocardial hypertrophy and fibrosis damage caused by the diabetes, reduce the contentof related myocardial enzymes, adjust the lipid metabolism level and improve myocardial cell oxidative stress and mitochondrial damage, so that the effect of protecting the heart is achieved; and therefore, the polypeptide can be used as a candidate molecule for treating or preventing the diabetes complicated with the cardiovascular diseases (especially diabetic cardiomyopathy), and has a good application prospect.